Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 51Colorectal Neoplasms 44Carcinoma, Hepatocellular 36Rectal Neoplasms 26Lung Neoplasms 23Colonic Neoplasms 22Neoplasm Metastasis 18Esophageal Neoplasms 18Cholangiocarcinoma 15Breast Neoplasms 13Stomach Neoplasms 12Glioma 11Ovarian Neoplasms 10Melanoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Renal Cell 9Anus Neoplasms 9Sarcoma 8Uterine Cervical Neoplasms 7Prostatic Neoplasms 7Medulloblastoma 7Lymphoma, Non-Hodgkin 7Ependymoma 7Carcinoma, Transitional Cell 7Brain Neoplasms 7Adenocarcinoma Of Esophagus 7Wilms Tumor 6Rhabdomyosarcoma 6Rhabdoid Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6

Interventions

Gemcitabine 6Cisplatin 6Capecitabine 6Liver Transplantation 4Fluorouracil 4Specimen Handling 3Radiosurgery 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3toripalimab 2dehydroftorafur 2Self Expandable Metallic Stents 2Platinum 2Leucovorin 2Biopsy 23-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 21,2-diaminocyclohexaneplatinum II citrate 2trisacryl gelatin microspheres 1tremelimumab 1trametinib 1tislelizumab 1temoporfin 1sacituzumab govitecan 1ricolinostat 1pembrolizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1durvalumab 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Klatskin Tumor × Magnetic Resonance Spectroscopy × Gastrointestinal × Clear all
NCT05564403 2026-05-13

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
66 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

University of Kansas Medical Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT06420349 2025-12-22

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Terminated
7 enrolled
Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡